Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva Andi, Veeva OpenData, Veeva Link, Veeva Network Customer Master, Veeva Crossix, Veeva Data Cloud, and MyVeeva for Doctors; and Veeva Vault, a cloud-based enterprise content and data management applications for managing commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. It also provides professional and support services in the areas of implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; technical consulting services related to data migration and systems integrations; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
IPO Year: 2013
Exchange: NYSE
Website: veeva.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2025 | $270.00 → $300.00 | Buy | Needham |
| 1/23/2025 | $261.00 → $200.00 | Buy → Sell | Goldman |
| 12/20/2024 | $280.00 | Overweight | Stephens |
| 12/4/2024 | $275.00 | Outperform | Mizuho |
| 11/19/2024 | $235.00 | Sector Perform | Scotiabank |
| 10/8/2024 | $286.00 | Outperform | Exane BNP Paribas |
| 8/27/2024 | $256.00 → $273.00 | Buy | Citigroup |
| 7/9/2024 | $240.00 | Buy | BTIG Research |
| 10/25/2023 | $211.00 → $229.00 | Equal Weight → Overweight | Wells Fargo |
| 10/13/2023 | $265.00 | Buy | Jefferies |
More than 50 medtech companies, including 11 of the top 20, have adopted Veeva clinical applications for greater efficiency and speed PLEASANTON, Calif., June 11, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected Veeva Clinical Platform applications to simplify and streamline medical device and diagnostics studies. With increasing regulatory requirements and evolving markets, medtech companies are moving away from siloed legacy solutions to modern connected applications from Veeva MedTech.
Industry focused on automation, connectivity, and reporting for proactive quality management PLEASANTON, Calif., June 9, 2025 /PRNewswire/ -- The 2025 Veeva MedTech Postmarket Quality Benchmark Report reveals that 88% of the medtech companies surveyed are advancing postmarket quality management within the next three years to improve compliance and drive innovation. This signals a shift toward modernization to reduce risk and foster a stronger culture of quality across the product lifecycle. While the move to more scalable solutions is planned or underway for most, 68% of medte
Vault CRM will support Astellas' commercial agility and execution PLEASANTON, Calif., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and deliver transformative therapies for patients around the world," said Nick Eshkenazi, chief digital and transformation officer at Astellas. "Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a co
Leading oncology research organization adopts Veeva Clinical Platform to enhance study delivery PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites.
PLEASANTON, Calif., May 30, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced participation in the following investor conferences: Baird 2025 Global Consumer, Technology & Services Conference, New York, NY. Paul Shawah, EVP Strategy, is presenting on Tuesday, June 3, 2025, at 10:50 a.m. Eastern Time.William Blair 45th Annual Growth Stock Conference, Chicago, IL. Brian Van Wagener, CFO, is presenting on Wednesday, June 4, 2025, at 1:20 p.m. Central Time.The above presentations will be webcast. Links to the live and archived webcast will be available on Veeva's investor relations website at https://ir.veeva.com. About Veeva SystemsVeeva is the global leader in cloud software for
Content effectiveness, not creation, is the goal that drives highest impact PLEASANTON, Calif., May 29, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today released the latest insights from its Veeva Pulse Field Trends Report, showing effective content-driven engagement remains one of the top drivers of new treatment adoption — not just content generation. While AI is helping speed content creation at scale, data shows that focusing on the right materials accelerates treatment starts, expands access, reduces time between meetings, and increases the likelihood of a follow-up conversation.
Total Revenues of $759.0M, up 17% Year Over YearSubscription Services Revenues of $634.8M, up 19% Year Over Year PLEASANTON, Calif., May 28, 2025 /PRNewswire/ -- Veeva Systems Inc. (NYSE:VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its first quarter ended April 30, 2025. "I consider this our best first quarter ever. We executed with speed, quality, and innovation across all areas on short-term objectives and long-term initiatives aligned to our values and 2030 goals," said CEO Peter Gassner. "Thanks t
Delivers pre-configured, pre-validated software that can scale with the needs of fast-growing companies PLEASANTON, Calif., May 20, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that Veeva Basics is being used by more than 75 biotechs to gain efficiency and reduce costs across clinical, regulatory, and quality. With standardized applications, biotechs are going live with industry-leading software in weeks and gaining a system that can scale as they expand their business. The rapid adoption of Veeva Basics signals a shift from disparate entry-level tools toward complete, best-of-breed solutions that can support biotechs today and as they grow.
PLEASANTON, Calif., May 7, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) will announce financial results for its first quarter, which ended April 30, 2025, after market close on May 28, 2025. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results. Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event. Event: Veeva Systems' Fiscal 2026 First Quarter Results Conference Call Date: Wednesday, May 28, 2025 Time: 2:00 p.m. PT (5:00 p.m. ET) Conference Call Registration: https:/
AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, and more share strategies for more connected customer experiences across sales, marketing, and medical PLEASANTON, Calif., May 6, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced its keynote speakers for the 2025 Veeva Commercial Summit, May 13-14 in Boston. Leading and emerging biopharmas will share innovations and strategies to drive more coordinated customer engagement through effective use of AI and alignment across data, content, and teams. Veeva CEO Peter Gassner will headline the opening keyn
Needham reiterated coverage of Veeva Systems with a rating of Buy and set a new price target of $300.00 from $270.00 previously
Goldman downgraded Veeva Systems from Buy to Sell and set a new price target of $200.00 from $261.00 previously
Stephens initiated coverage of Veeva Systems with a rating of Overweight and set a new price target of $280.00
Mizuho initiated coverage of Veeva Systems with a rating of Outperform and set a new price target of $275.00
Scotiabank initiated coverage of Veeva Systems with a rating of Sector Perform and set a new price target of $235.00
Exane BNP Paribas initiated coverage of Veeva Systems with a rating of Outperform and set a new price target of $286.00
Citigroup reiterated coverage of Veeva Systems with a rating of Buy and set a new price target of $273.00 from $256.00 previously
BTIG Research initiated coverage of Veeva Systems with a rating of Buy and set a new price target of $240.00
Wells Fargo upgraded Veeva Systems from Equal Weight to Overweight and set a new price target of $229.00 from $211.00 previously
Jefferies initiated coverage of Veeva Systems with a rating of Buy and set a new price target of $265.00